Zoetis Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $ZTS in the last 30 days.
See all $ZTS insider activity →Zoetis (ZTS) reported flat Q2 revenue of $2.47B, missing estimates, and lowered full-year guidance. Supernus Pharmaceuticals (SUPN) reported 27.7% revenue growth to $211.3M, beating estimates. Eli Lilly (LLY) reported 47.7% revenue growth to $22.97B, significantly beating estimates. All three stocks have risen since reporting.
Zoetis (ZTS) stock rose 3.61% in a day and 6.52% in a week after FDA authorized Simparica Trio for treating New World screwworm. Despite recent gains, shares are down 38.27% year-to-date and 48.95% in a year. The company lowered revenue and earnings guidance, with a 11% YoY decline in U.S. Companion Animal segment revenue. ValueInvestingSubstack values Zoetis at $92.92, suggesting a 16.3% undervaluation.
Zoetis Inc. (NYSE:ZTS) received emergency authorization for Simparica Trio to treat New World screwworm in dogs. This follows a 7% decline in U.S. revenue and 11% drop in domestic companion-animal product sales. The authorization expands the product's use, potentially supporting its lifecycle amid competitive pressure and macroeconomic sensitivity.
Over the past 7 days, alphai's AI scored 6 news stories mentioning ZTS (Zoetis Inc.). Coverage has skewed bearish: 2 bullish, 1 neutral, and 3 bearish.
Recent ZTS coverage spans earnings, regulation and market movers.
Weak earnings may pressure the stock despite short-term rally.
Regulatory approval expands product portfolio and may boost sales in the companion animal market.
Regulatory approval expands product use, potentially boosting sales and supporting revenue amid recent U.S. decline.
Mixed earnings signal pressure on the core pet‑care segment while livestock growth offers upside.
Weak earnings may pressure the stock despite the small price uptick.
alphai scores every news story that mentions ZTS with an AI model for sentiment and relevance, and aggregates insider trades from Zoetis Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Zoetis (ZTS) reported flat Q2 revenue of $2.47B, missing estimates, and lowered full-year guidance. Supernus Pharmaceuticals (SUPN) reported 27.7% revenue growth to $211.3M, beating estimates. Eli Lilly (LLY) reported 47.7% revenue growth to $22.97B, significantly beating estimates. All three stocks have risen since reporting.
3 min readZoetis (ZTS) stock rose 3.61% in a day and 6.52% in a week after FDA authorized Simparica Trio for treating New World screwworm. Despite recent gains, shares are down 38.27% year-to-date and 48.95% in a year. The company lowered revenue and earnings guidance, with a 11% YoY decline in U.S. Companion Animal segment revenue. ValueInvestingSubstack values Zoetis at $92.92, suggesting a 16.3% undervaluation.
2 min readZoetis Inc. (NYSE:ZTS) received emergency authorization for Simparica Trio to treat New World screwworm in dogs. This follows a 7% decline in U.S. revenue and 11% drop in domestic companion-animal product sales. The authorization expands the product's use, potentially supporting its lifecycle amid competitive pressure and macroeconomic sensitivity.
2 min readZoetis (NYSE:ZTS) reported flat Q2 2026 revenue of $2.5B, down 1% organically, with U.S. companion-animal sales declining 11% due to price sensitivity and competition. Livestock and international sales grew 12% and 8%, respectively. The company highlighted a pipeline of 12 potential blockbuster products and recent acquisitions to drive future growth.
2 min readBristol-Myers Squibb (BMY) reported Q2 revenues of $12.97B, up 5.7% YoY, beating estimates. Zoetis (ZTS) reported flat revenues of $2.47B, missing estimates. Amphastar (AMPH) reported $183.9M in revenues, up 5.4% YoY, beating estimates. Eli Lilly (LLY) reported $22.97B in revenues, up 47.7% YoY, beating estimates. Market sentiment has shifted from AI to geopolitics.
3 min readBenzinga reports unusual options activity in 10 healthcare stocks. Notable trades include bullish calls on SELLAS Life Sciences (SLS) at $30 strike, bearish calls on Zoetis (ZTS) at $85 strike, and bullish puts on Lilly (LLY) at $1260 strike. Other stocks with notable activity include NBIX, AGEN, BBIO, BSX, NVO, and CAPR.
2 min readCentene's CFO Drew Asher to step down by year-end, succeeded by Chris Neczypor. Baxter International names John Rogers as CFO. GE HealthCare appoints William K. Grogan as CFO. QVC Group's CEO David Rawlinson steps down, Mike George takes interim role. Changes impact leadership at Fortune 500 companies.
3 min readZoetis (ZTS) reported flat Q2 2026 sales of $2.47B and lower net income of $691M. The company cut full-year 2026 guidance to revenue of $9.12B-$9.32B and EPS of $5.55-$5.65. Zoetis also secured FDA EUA for Simparica Trio and appointed a new CFO and COO. Investors are reassessing the company's growth narrative amid these changes.
5 min readGE HealthCare said CFO Jay Saccaro will leave Aug. 14 to become Zoetis’ newly created EVP, CFO and COO on Aug. 17, overseeing global finance plus manufacturing and supply. GE HealthCare named George Newcomb interim CFO. The company reported Q2 revenue of $5.3B, up 5.7%, organic growth 3.5%, orders up 11.1%, backlog $23.9B, and reaffirmed 2026 guidance.
4 min readZoetis said it received VMD approval for Portela (relfovetmab injection), a long-acting anti-NGF monoclonal antibody for cats with osteoarthritis pain. The company says a single subcutaneous dose can last up to three months, with pain improvements noted from day three in a nine-month European field study and good tolerability in trials. It follows Zoetis’ May approval of Lenivia for dogs.
2 min read
